RecruitingPhase 1Phase 2NCT05371145

Carnosine for Peripheral Arterial Disease Patients

Carnosine for Peripheral Arterial Disease Patients (Car-PAD)


Sponsor

Shahid Baba

Enrollment

20 participants

Start Date

Mar 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.


Eligibility

Sex: MALEMin Age: 50 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Carnosine for people with peripheral arterial disease. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 50 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCarnosine

Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.


Locations(1)

University of Louisville

Louisville, Kentucky, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05371145


Related Trials